Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients - Sorbonne Université Access content directly
Journal Articles Revue Neurologique Year : 2022

Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients

Abstract

Background and purpose Long-term outcomes after neurological manifestations due to COVID-19 are poorly known. The aim of our study was to evaluate the functional outcome and identify the risk factors of neurologic sequelae after COVID-19 associated with neurological manifestations (NeuroCOVID). Methods We conducted a multi-center observational study six months after the acute neurological symptoms in patients from the French NeuroCOVID hospital-based registry. Results We obtained data on 60 patients. NeuroCOVID had a negative impact on the quality of life (QoL) of 49% of patients. Age was a predictor of residual QoL impairment (OR: 1.06, 95% CI: 1.01–1.13, p = 0.026). At six months, a significant residual disability was found in 51.7% of patients, and impaired cognition in 68.9% of cases. The main persistent neuropsychiatric manifestations were a persistent smell/taste disorder in 45% of patients, memory complaints in 34% of patients, anxiety or depression in 32% of patients. Conclusions NeuroCOVID likely carries a high risk of long-term neuropsychiatric disability. Long-term care and special attention should be given to COVID-19 patients, especially if they had neurological manifestations during acute infection.
Fichier principal
Vignette du fichier
1-s2.0-S0035378721007943-am.pdf (258 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04573166 , version 1 (13-05-2024)

Identifiers

Cite

Hugo Chaumont, E. Meppiel, E. Roze, B. Tressières, T. de Broucker, et al.. Long-term outcomes after NeuroCOVID: A 6-month follow-up study on 60 patients. Revue Neurologique, 2022, 178 (1-2), pp.137-143. ⟨10.1016/j.neurol.2021.12.008⟩. ⟨hal-04573166⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More